Alaunos Therapeutics, Inc.
TCRT
$3.69
$0.133.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 153.51% | -46.69% | |||
| Gross Profit | -153.51% | 46.38% | |||
| SG&A Expenses | -15.93% | 14.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.24% | -5.03% | |||
| Operating Income | -14.24% | 4.85% | |||
| Income Before Tax | -10.28% | 2.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.28% | 2.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.28% | 2.05% | |||
| EBIT | -14.24% | 4.85% | |||
| EBITDA | -14.25% | 4.86% | |||
| EPS Basic | 15.33% | 6.43% | |||
| Normalized Basic EPS | 15.31% | 6.45% | |||
| EPS Diluted | 15.33% | 6.43% | |||
| Normalized Diluted EPS | 15.31% | 6.45% | |||
| Average Basic Shares Outstanding | 30.23% | 4.68% | |||
| Average Diluted Shares Outstanding | 30.23% | 4.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||